Conatus Pharmaceuticals Inc (NASDAQ:CNAT) announced positive top-line results from the three-month, open-label second stage of the company’s multicenter Phase 2 clinical trial of emricasan, …
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) announced the delivery of a late breaker oral presentation at The International Liver Congress™ 2016, the Annual Meeting of the …
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) announced that a poster addressing results in bothex vivo cell culture and in vivo mouse models of hepatocellular carcinoma with …
Conatus Pharmaceuticals Inc (NASDAQ:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, announced the appointment …
Healthcare analysts weigh in today on insulin drug maker MannKind Corporation (NASDAQ:MNKD) and biotechnology company Conatus Pharmaceuticals Inc (NASDAQ:CNAT). While one analyst is quite bearish on MannKind …
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced that the U.
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) announced the initiation of active patient recruitment in ENCORE-NF, a randomized, double-blind, placebo-controlled, Phase 2b clinical trial evaluating emricasan, the …
Analysts weigh in on biotechnology company Conatus Pharmaceuticals Inc (NASDAQ:CNAT) and vision chip company Mobileye NV (NYSE:MBLY), as news of positive Phase II study of liver cirrhosis and strategic …
Netflix, Inc. (NASDAQ:NFLX) is down 2.
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) announced the presentation of two posters, both addressing preclinical results with the company’s pan-caspase inhibitors, at The Liver Meeting®, the …
